Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Open access
Mosenzon, Ofri, Blicher, Thalia Marie, Rosenlund, Signe, Eriksson, Jan W, Heller, Simon, Hels, Ole Holm, Pratley, Richard, Sathyapalan, Thozhukat, Desouza, Cyrus, Abramof, R, Alpenidze, D, Aronoff, S, Astamirova, K, Barker, B, Bedel, G, Belousova, L, Benson, M, Beshay, I, Biggs, W, Blaze, K, Bogdanski, P, Busch, R, Chaidarun, S, Chandran, S, Chang, A, Chilka, S, Cleland, A, Connery, L, Cornett, G, Delgado, B, Desouza, C, Donner, T, Eliasson, K, Eriksson, J, Folkerth, S, Forshaw, K, Frandsen, H A, Frolova, E, Gandy, W, Gatipon, G, Golovach, A, Gonzalez-Orozco, L, Gumprecht, J, Haddad, E, Hansen, T K, Hart, T, Hasan, S, Hella, B, Heller, S, Hellgren, M, Hewitt, M, Hietaniemi, S, Hitz, M, Houser, P, Huntley, R, Jackson, R, Jakobsen, P E, Kapoor, A, Kargina, L, Kazakova, E, Khan, K, Klein, E, Knoble, H, Krasnopeeva (Kabachkova), N, Krzeminski, A, Kunitsyna, M, Lawhead, J, Levin, K, Levin, P, Lewy-Alterbaum, L, Lindmark, S, Lindsay, R, Luts, A, Lysenko, T, Madsbad, S, Maxwell, T, Mbogua, C, Mcknight, J, Metsärinne, K, Milovanova, T, Morawski, E, Mosenzon, O, Nabriski, D, Nguyen, H, Nicol, P, Nieminen, S, Nikkola, A, Norwood, P, O'Donnell, P, Odugbesan, A, Parker, J, Pergaeva, Y, Peskov, A, Plevin, S, Pouzar, J, Pratley, R, Reed, J, Rossing, P, Sathyapalan, T, Sergeeva-Kondrachenko, M, Shaikh, Z, Shamkhalova, M, Shehadeh, N, Shlesinger, Y, Silver, R, Snyder, B, Soufer, J, Strand, J, Sulosaari, S, Tirosh, A, Traylor, H, Uhlenius, N, Vagapova, G, Yanovskaya, M, Zarutskaya, L, Zhdanova, E · 2019 · The Lancet Diabetes & Endocrinology

Abstract

Background Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We aimed to investigate the efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment.Methods This randomised, double-blind, phase 3a trial was undertaken at 88 sites in eight countries. Patients aged 18 years and older, with type 2 diabetes, an estimated glomerular filtration rate of 30-59 mL/min per 1·73 m 2, and who had been receiving a stable dose of metformin or sulfonylurea, or both, or basal insulin with or without metformin for the past 90 days were eligible. Participants were randomly assigned (1:1) by use of an interactive web-response system, with stratification by glucose-lowering medication and renal function, to receive oral semaglutide (dose escalated to 14 mg once daily) or matching placebo for 26 weeks, in addition to background medication. Participants and site staff were masked to assignment. Two efficacy-related estimands were defined: treatment policy (regardless of treatment discontinuation or rescue medication) and trial product (on treatment without rescue medication) in all participants randomly assigned. Endpoints were change from baseline to week 26 in HbA 1c (primary endpoint) and bodyweight (confirmatory secondary endpoint), assessed in all participants with sufficient data. Safety was assessed in all participants who received at least one dose of study drug. This trial is registered on ClinicalTrials.gov, number NCT02827708, and the European Clinical Trials Registry, number EudraCT 2015-005326-19, and is now complete.Findings Between Sept 20, 2016, and Sept 29, 2017, of 721 patients screened, 324 were eligible and randomly assigned to oral semaglutide (n=163) or placebo (n=161). Mean age at baseline was 70 years (SD 8), and 168 (52%) of participants were female. 133 (82%) participants in the oral semaglutide group and 141 (88%) in the placebo group completed 26 weeks on treatment. At 26 weeks, oral semaglutide was superior to placebo in decreasing HbA 1c (estimated mean change of -1·0 percentage point (SE 0·1; -11 mmol/mol [SE 0·8]) vs -0·2 percentage points (SE 0·1; -2 mmol/mol [SE 0·8]); estimated treatment difference [ETD]: -0·8 percentage points, 95% CI -1·0 to -0·6; p<0·0001) and bodyweight (estimated mean change of -3·4 kg [SE 0·3] vs -0·9 kg [SE 0·3]; ETD, -2·5, 95% CI -3·2 to -1·8; p<0·0001) by the treatment policy estimand. Significant differences were seen for the trial product estimand: mean change in HbA 1c -1·1 percentage points (SE 0·1; -12 mmol/mol [SE 0·8] versus -0·1 percentage points (SE 0·1; -1 mmol/mol [SE 0·8]; ETD -1·0 percentage points, 95% CI -1·2 to -0·8; p<0·0001); mean change in bodyweight -3·7 kg (SE 0·3) versus -1·1 kg (SE 0·3; ETD -2·7 kg, 95% CI -3·5 to -1·9; p<0·0001). More patients taking oral semaglutide than placebo had adverse events (120 [74%] of 163 vs 105 [65%] of 161), and discontinued treatment as a result (24 [15%] vs eight [5%]). Gastrointestinal events, mainly mild-to-moderate nausea, were more common with oral semaglutide than with placebo. Three deaths occurred during the treatment period that were not condsidered to be treatment related, one in the semaglutide group and two in the placebo group.Interpretation Oral semaglutide was effective in patients with type 2 diabetes and moderate renal impairment, potentially providing a new treatment option for this population. Safety, including renal safety, was consistent with the GLP-1 receptor agonist class.Funding Novo Nordisk A/S.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(19)30192-5

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. 2018, 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018, Diabetes Care, 41, S73

Cited by

See all 351

Metadata

Authors
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., Alpenidze, D., Aronoff, S., Astamirova, K., Barker, B., Bedel, G., Belousova, L., Benson, M., Beshay, I., Biggs, W., Blaze, K., Bogdanski, P., Busch, R., Chaidarun, S., Chandran, S., Chang, A., Chilka, S., Cleland, A., Connery, L., Cornett, G., Delgado, B., Desouza, C., Donner, T., Eliasson, K., Eriksson, J., Folkerth, S., Forshaw, K., Frandsen, H. A., Frolova, E., Gandy, W., Gatipon, G., Golovach, A., Gonzalez-Orozco, L., Gumprecht, J., Haddad, E., Hansen, T. K., Hart, T., Hasan, S., Hella, B., Heller, S., Hellgren, M., Hewitt, M., Hietaniemi, S., Hitz, M., Houser, P., Huntley, R., Jackson, R., Jakobsen, P. E., Kapoor, A., Kargina, L., Kazakova, E., Khan, K., Klein, E., Knoble, H., Krasnopeeva (Kabachkova), N., Krzeminski, A., Kunitsyna, M., Lawhead, J., Levin, K., Levin, P., Lewy-Alterbaum, L., Lindmark, S., Lindsay, R., Luts, A., Lysenko, T., Madsbad, S., Maxwell, T., Mbogua, C., Mcknight, J., Metsärinne, K., Milovanova, T., Morawski, E., Mosenzon, O., Nabriski, D., Nguyen, H., Nicol, P., Nieminen, S., Nikkola, A., Norwood, P., O'Donnell, P., Odugbesan, A., Parker, J., Pergaeva, Y., Peskov, A., Plevin, S., Pouzar, J., Pratley, R., Reed, J., Rossing, P., Sathyapalan, T., Sergeeva-Kondrachenko, M., Shaikh, Z., Shamkhalova, M., Shehadeh, N., Shlesinger, Y., Silver, R., Snyder, B., Soufer, J., Strand, J., Sulosaari, S., Tirosh, A., Traylor, H., Uhlenius, N., Vagapova, G., Yanovskaya, M., Zarutskaya, L., & Zhdanova, E.
Affiliations
  • Novo Nordisk (Denmark) (DK)
  • University of Nebraska Medical Center (US)
  • Uppsala University (SE)
  • University of Hull (GB)
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2019-07
Volume
7
Issue
7
Pages
515-527
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2948370538
Cited by
351
References
38
Citations by year
2026: 32 · 2025: 63 · 2024: 62 · 2023: 41 · 2022: 41 · 2021: 45 · 2020: 50 · 2019: 15
FWCI
30.64
Type
journal article
Language
en
Open access
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (acceptedVersion, cc-by-nc-nd)
  • Scopus (Elsevier) (submittedVersion)
Funders
  • AstraZeneca
  • Boehringer Ingelheim
  • National Institutes of Health
  • Bristol-Myers Squibb
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
ide, type 2 diabetes, renal dysfunction, GLP-1 receptor agonists, HbA1c, body weight, drug safety, adverse events, renal function, metformin, sulfonylureas, basal insulin, treatment discontinuation, rescue medication, older adults, dose escalation, weight loss
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Aged, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Humans, Male, Middle Aged, Treatment Outcome, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30192-5
The paper
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., Alpenidze, D., Aronoff, S., Astamirova, K., Barker, B., Bedel, G., Belousova, L., Benson, M., Beshay, I., Biggs, W., . . . Zhdanova, E. (2019). Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30192-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.